MAPT and Alzheimer disease: At the same time, RSBFL treatment can reduce abnormal phosphorylation of Tau protein at Thr231 and Ser9 sites, which further suggests the function of RSBFL to suppress excessive abnormal phosphorylation of Tau and reduce the expression level of p-Tau in AD cells.